Replimune Group, Inc. (REPL)

5,27 +0,17 (+3,33%) Alla chiusura: 04:00PM EDT

Replimune Group, Inc.

500 Unicorn Park Drive
Suite 303
Woburn, MA 01801
United States
781 222 9600
https://www.replimune.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 331

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Philip Astley-Sparke F.S.A.	Executive Chairman	1,07M	N/D	1971
Dr. Sushil Patel Ph.D.	Chief Executive Officer	665,05k	N/D	1971
Dr. Robert Coffin Ph.D.	Founder, Chief Scientist & Director	785,89k	N/D	1965
Ms. Emily Luisa Hill	Chief Financial Officer	N/D	N/D	1980
Mr. Andrew Schwendenman	Chief Accounting Officer & Treasurer	N/D	N/D	1976
Mr. Christopher Sarchi	Chief Commercial Officer	N/D	N/D	1968
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.	Chief Medical Officer	N/D	N/D	1966
Mr. Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Replimune Group, Inc. al 1 giugno 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.